+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The comparative survival of TNF-blocking agents in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis during one-year follow-up: Results from a longitudinal, observational study



The comparative survival of TNF-blocking agents in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis during one-year follow-up: Results from a longitudinal, observational study








Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 021901260

Download citation: RISBibTeXText


Related references

The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis and Rheumatism 59(2): 234-240, 2008

The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study. Arthritis and Rheumatism 52(8): 2506-2512, 2005

Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis. Wiener Medizinische Wochenschrift 160(9-10): 220-224, 2010

High 3-year golimumab survival in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: real world data from 328 patients. Clinical and Experimental Rheumatology 36(2): 254-262, 2017

Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis. Journal of Rheumatology 43(12): 2120-2130, 2016

Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry. Annals of the Rheumatic Diseases 74(3): E12, 2015

Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology 49(8): 1570-1577, 2011

Treatment patterns among patients with rheumatic disease (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated arthritis (UnA)) treated with subcutaneous TNF inhibitors. Clinical Rheumatology 37(6): 1617-1623, 2018

AB1120Comparison of Long-Term Drug Survival of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis: A Single Center Turkish Experience Over a Decade. Annals of the Rheumatic Diseases 74(Suppl 2): 1275.2-1276, 2015

Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opinion on Drug Safety 15(Sup1): 35-54, 2016

Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opinion on Drug Safety 15(Sup1): 11-34, 2016

AB0148Vitamin D Deficiency in Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis. Results of the Carma Study. Annals of the Rheumatic Diseases 74(Suppl 2): 940.1-940, 2015

Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry. Clinical and Experimental Rheumatology 35(5): 804-809, 2017

Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Annals of the Rheumatic Diseases 72(4): 517-524, 2013

SAT0130Long-term safety of adalimumab in patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, and crohns disease:. Annals of the Rheumatic Diseases 71(Suppl 3): 514.3-515, 2013